

WOMAN'S OVERWEIGHT PROBLEMS DURING PREGNANCY, CONCEPTION, AND OFFSPRING'S HEALTH

Dr. LAXMI GUPTA

Researcher University of Patanjali, Haridwar, India.

Abstract

We are all aware of the epidemic this is female weight problems, which regularly coexist with endocrine and metabolic problems. Obese ladies are much more likely to have reproductive issues, including infertility, defects in embryo improvement, and unusual offspring. There are many mechanisms at play with the outcomes of obesity and weight problems at the improvement of those reproductive problems in ladies, making women weight problems a complicated multifactorial condition. Important mechanisms consist of insulin resistance, hyperinsulinemia, hyperandrogenism, lipotoxicity, and inflammation. The specific mechanism underlying their correlation remains unknown, though. Fortunately, it's been observed that weight reduction strategies can oppose the poor outcomes of maternal weight problems on fertility, the foetus, and the offspring.

KEYWORDS: Overweight, infertility, embryonic growth, progeny, nephropathy, and cardiac illness.

Introduction

Obesity and obese are each characterized via way of means of an abnormal or immoderate fat build-up that may be dangerous to fitness. BMI needs to be used to categorize individuals who're obese or overweight, in line with the World Health Organization (WHO). BMI is calculated by dividing weight in kilograms through height in rectangular meters (kg/m^2). Adults with a BMI below 25 are taken into consideration as obese, and people with a BMI over 30 are taken into consideration as overweight (1). Obesity incidence has extended alarmingly during the last few long time and is already at epidemic levels. Overweight weight problems affected an expected 1.9 billion and 609 million individuals globally in 2015, accounting for around 39% of the world's population, and commonly speaking, ladies revel in more costs of weight problems than males (2). Numerous continual diseases, including cardiovascular disorders, hypertension, diabetes, or even numerous cancers (including endometrial, breast, and colon cancers), are made much more likely through weight problems, consistent with the research (3). Additionally, a developing frame of research has proven that overweight ladies have a high risk of getting terrible reproductive fitness. They regularly have a compromised reproductive fitness status, that's related to terrible fertilization, aberrant embryo development, terrible offspring growth, and disorder susceptibility (4–6). Therefore, in this study, we provide a précis of what's presently acknowledged on how weight problems impact fertility, pregnancy outcomes, and the fitness of kids.

Female infertility and obesity

Infertility impacts one in seven ladies of reproductive age in prosperous countries and one in 4 ladies in underdeveloped countries, consistent with the research. Infertility fees may even exceed 30% in some areas of the world, which includes South Asia, the

Middle East, and Central Asia (7). Numerous conditions, including endometriosis, vaginal infections, uterine abnormalities, tubal deformities, and endocrine problems can lead to infertility (8). But overweight problem, which is now diagnosed as a separate danger factor for woman's infertility, is one of the major reasons for infertility in ladies. Overweight ladies are 3 instances as possibly as normal-weight ladies to revel in infertility (9). In ladies, weight problems are characterized by an unusual or excessive fat build-up. Infertility can result from having an excessive amount of fats, especially visceral adipose tissue, which could stimulate the adrenal and ovarian glands, produce an excessive amount of testosterone, reason month-to-month issues, and stimulate the ovaries. So there are numerous methods that fats contribute to infertility. Women of childbearing age are much more likely to increase menstruation abnormalities if they're overweight as kids or teenagers. Obese humans appear to revel in extra abnormal menstrual intervals than the ones of common weight. Menstrual cycle issues were determined in 30% to 47% of obese or overweight ladies (10).

Obesity is a metabolic infection; this is commonly followed through increased ranges of circulating insulin and increased ovarian androgen manufacturing (11). Then, the lot of adipose tissue reasons the androgens to aromatize into estrogen, which has the impact of a terrible comment on the hypothalamic-pituitary axis (HPO) and decreases gonadotropin output (12). Different gonadotropin features are concerned with follicle growth, oocyte maturation, and corpus luteal manufacturing (13). As a result, the reduced gonadotropin ranges reason for abnormal menstruation cycles, infertility, and suppression of ovarian function. In human pregnancy, the embryo first adheres to the uterine luminal epithelium before getting into the endometrial stoma, in which the stromal cells mature into decidual cells and feed the developing embryo (14). The synthesis of numerous materials through the adipose tissue, which includes leptin, loose fatty acids (FFA), and cytokines, may also affect how the endometrium operates. Studies have discovered that animals with diet-triggered weight problems (DIO) had terrible endometrial decasualization (15). The frequency of implantation websites and the endometrial stromal molecular reaction to hormonal stimulation have been considerably decreased in the DIO animals as compared to mice on a normal diet. Similar to this, overweight ladies' human endometrial stromal cells have much less cap potential to undergo normal decasualization, which can restrict endometrial receptivity. The best endometrial receptivity, as is properly known, guarantees success in embryo implantation (16). As a result, infertility and unsuccessful embryo implantation in overweight ladies are due to decreased endometrial receptivity. Insulin resistance and hyperandrogenism are the underlying reasons for the extensive endocrine anomaly called polycystic ovarian syndrome (PCOS), which impacts ladies of reproductive age. Nearly 30% of overweight girls have PCOS, but weight problems aren't continually the basis reason for PCOS (17). A bidirectional courting among weight problems and PCOS is supported through dependable data. Because it reasons insulin resistance and the discharge of adipokine, an overweight problem makes the symptoms and symptoms and signs and symptoms of PCOS worse (18). According to current research, visceral fats contribute to insulin resistance by generating positive adipokine and fatty acids, which in flip reasons metabolic disorder in PCOS. On the alternative side, ladies with

PCOS are much more likely to advantage weight than ladies without PCOS, which can be due to abnormal power expenditure, improved androgen secretion, emotional problems related to PCOS, and bodily inactivity (19). There is, however, a loss of conclusive proof helping the function of PCOS in weight advantage, now no longer to say the underlying molecular process, for the reason that PCOS is a complex multifactorial condition. An aggregate of the 3 major signs and symptoms of PCOS—hyperandrogenism, ovarian disorder, and the lifestyles of polycystic ovaries—defines the condition (20). By selling atresia and apoptosis, improved ovarian androgen manufacturing may also inhibit follicular development. The resumption of ovulation in PCOS sufferers after an antiandrogen remedy for 6 months should function as proof of the function of androgens in ovulation. The follicular wall's collagenous tissue should be damaged throughout ovulation, and matrix metalloprotease (MMP) performs an important element in this process. Lysol oxidase (LOX) hobby became located to be up-regulated in reaction to androgens, while MMP2 hobby turned considerably down-regulated in an examination of the use of a dehydroepiandrosterone-triggered rat version of PCOS. This location indicates that androgens may also inhibit collagen breakdown and lead to anovulation in PCOS. In addition, as compared to ladies without PCOS, ladies with POCS have considerably extra tiny astral follicles and bring considerably extra anti-Müllerian hormone (AMH) from every follicle. With extra GnRH being secreted through hypothalamic neurons due to the expanded AMH ranges, the anterior pituitary gland might produce extra luteinizing hormone (LH), which might in the end inspire the ovary to provide progesterone instead than estradiol. The end-of-follicular segment untimely progesterone surge seems to hasten endometrial maturation and decrease endometrial receptivity, causing embryo-endometrium synchrony.

Obesity and fallacious embryonic development

According to statistics, 20 to 40 percent of pregnant ladies benefit from extra weight than is healthy, and one-5th of ladies are overweight earlier than getting pregnant. The frequency of weight problems in the course of pregnancy ranges from 1. Eight to 25.3%, consistent with the World Health Organization (WHO) (21). The lives of moms and babies are at risk because of maternal weight problems. Preterm birth, macrosomia, congenital abnormalities, preterm births, and perinatal loss of life are most of the deadly hazards. Compared to maternal hyperglycaemia, maternal weight problems are a concept to be a higher predictor of deadly macrosomia. (22). Pregnant women who are obese run a significantly higher risk of fetal macrosomia, which affects 20% of babies. It is known that pregnant women who are overweight have placentas that weigh more than those of pregnant women who are average weight (23). The placenta serves as a change interface for gas, nutrients, and waste merchandise between the mother and the fetus. It is made from a fetal portion (the chorion) and a maternal portion (the decidua). A delivery weight that is >4,000 g or over the 90th percentile for gestational age is called macrosomia. The weight of the placenta and the baby's delivery weight is relatively correlated. (24). Maternal hyperglycaemia introduced on through insulin resistance, collectively with accelerated placental glucose switch and endogenous fetal insulin production, may be used to explain the pathogenesis of macrosomia. As a result, fetal

adipose and protein tissues grow hyperplastically, and glucose utilization increases. The hyperlink between fetal increase difficulty and maternal obesity, however, becomes additionally visible in obese pregnant women, albeit the precise procedures underlying this hyperlink are yet unclear. Placental procedures, the motion of vitamins through the placenta, and genetic variables all play a primary position in the fetal boom. As a result, the fetal increase challenge that develops due to maternal weight problems can be related to the failure of the fetus to attain its complete increase potential. Meanwhile, as compared to pregnant ladies of regular weight, overweight girls are 30% more likely to revel in congenital malformations of the neural tube, heart, and limb (25). It is unknown exactly how maternal fats impact fetal increase. Obesity in mothers has been related to a better occurrence of gestational diabetes. Even after controlling for glucose levels, Brite et al. found no discernible reduction in the incidence of congenital cardiac disease, indicating that faulty glucose metabolism may not be the only factor contributing to the development of congenital abnormalities. Numerous metabolic abnormalities, similarly to glycaemic deregulation, play a position within side the etiology of obesity. Because of the numerous dangerous metabolic modifications in overweight pregnant women, the fetus may also have negative repercussions as a result.

The health of the offspring and obesity

The occurrence of future metabolic disorders and deformity inside the offspring is elevated through maternal obesity, as proven through a developing variety of studies. Adult obesity, kind 2 diabetes, renal disorder, hypertension, and cardiovascular disorder are more probably to arise in kids of overweight moms (26). According to a study, maternal obesity increased a child's chance of congenital kidney abnormalities by 22%. (27). additionally, glomerular harm inside the offspring of overweight mothers became worse than that inside the offspring of normal-weight mothers (28). The mechanism of maternal obesity-associated nephropathy in offspring is multifaceted. Kidney disease has been linked to abnormalities in lipid metabolism, according to reports (29). Free fatty acids (FAs) and triglycerides might be freely filtered and reabsorbed through glomerular Tubulointerstitial cells within side the pathophysiology of persistent kidney damage (30). Due to their potential to grow oxidative strain and inflammation, unfastened fatty acids function as a connection between adipose tissue hobby and persistent inflammation. (31). Reactive oxygen species, pro-fibrotic increase factors, and pro-inflammatory cytokines are produced as a result of the extra lipid, which leads to tubular fibrosis and irreparable tubular damage (32). Yang, and colleagues, ddiscovered in animal tests that inflammation enhances the cellular uptake of fatty acids, ultimately leading to glomerular injury (33). In addition, additional metabolic risk factors like hypertension, insulin resistance, and dyslipidaemia may potentially contribute to obesity-related nephropathy. Obesity in the mother is often linked to an increased incidence of congenital cardiac abnormalities in the baby, following epidemiological research (e.g. septal defects, construal defects, aortic arch defects). One-third of all severe malformations are caused by the most prevalent type of malformation, congenital cardiac abnormalities (34). Numerous researches has verified the hyperlink between growing fat mass and insulin resistance, hyperinsulinemia,

lipotoxicity, and inflammation, all of which may also damage embryo development (35). Additionally, it's been proposed that maternal weight problems may also inhibit stem cells' capability for self-renewal and regulate the embryo's epigenetic, inflicting coronary heart abnormalities (36). Some have additionally claimed that there's a better risk of weight problems in the kids of overweight mothers. Additionally, immoderate adipose tissue's elevated leptin secretion causes insulin resistance and inflammatory response, which immediately harms cardiovascular health. (37). Fatty tissue formation in obese offspring raises the left ventricle's stroke volume, adding to the heart's strain. These modifications would cause the ventricles to hypertrophy and expand, and they would even put patients at risk for developing heart failure (38). Losing weight and avoiding diseases that affect female reproduction. According to the information above, dropping pounds is essential to reducing the danger of obesity-associated reproductive problems. Women with short-time period weight reduction produce extensively greater mid-level II oocytes than overweight ladies in a medical examination related to 170 ladies' present process in vitro fertilization (39). Reduced-calorie food plans and exercise interventions are mentioned as powerful techniques for weight reduction in overweight ladies, which is related to improved ovulation and being pregnant fees for females. In a prospective examination related to 87 overweight ladies, the individuals made dietary, exercise, and lifestyle modifications for 6 months. Last but not least, the 67 women who finished the 6-month program lost 10.2 kg/m² on average. 90% of ladies resumed spontaneous ovulation, 77.6% got here pregnant (32.7% spontaneously), and 67% gave delivery to residing babies (40). In contrast, none of these modifications took place in the women who discontinued the medication. Therefore, weight decrease can resource in ovulation, pregnancy, and stay birth, and ladies with an excessive BMI have to be recommended to achieve this before getting pregnant.

Conclusion

In conclusion, weight problems in ladies will increase the threat of infertility and has unfavorable results for the growing fetus and the child. Fortunately, mild weight reduction can save you those terrible effects. Further, examine is wanted to higher recognize the relationship between weight problems and woman replica to defend the fitness of extra ladies.

References

1. Blüher M. Metabolically healthy obesity. *Endocr Rev.* (2020) 41(3):bnaa004. doi: 10.1210/edrv/bnaa004
2. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. *Metabolism* (2019) 92:6–10. doi: 10.1016/j.metabol.2018.09.005
3. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. *Int J Obes (Lond)* (2008) 32(9):1431–7. doi: 10.1038/ijo.2008.102
4. Davis AM. Collateral damage: maternal obesity during pregnancy continues to rise. *Obstet Gynecol Surv* (2020) 75(1):39–49. DOI: 10.1097/OGX.0000000000000734
5. Stang J, Huffman LG. Position of the academy of nutrition and dietetics: Obesity, reproduction, and pregnancy outcomes. *J Acad Nutr Diet* (2016) 116 (4):677–91. DOI: 10.1016/j.jand.2016.01.008

6. Wong MG, The NL, Glastras S. Maternal obesity and offspring risk of chronic kidney disease. *Nephrol (Carlton)* (2018) 23 Suppl 4:84–7. DOI: 10.1111/nep.13462
7. Ou XH, Zhu CC, Sun SC. Effects of obesity and diabetes on the epigenetic modification of mammalian gametes. *J Cell Physiol* (2019) 234(6):7847–55. DOI: 10.1002/jcp.27847
8. Zalányi S. Progesterone and ovulation. *Eur J Obstet Gynecol Reprod Biol* (2001) 98(2):152–9. doi: 10.1016/s0301-2115(01)00361-x
9. Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity's impact. *Fertil Steril* (2017) 107(4):840–7. doi: 10.1016/j.fertnstert.2017.01.017
10. Xu H, Li PH, Barrow TM, Colicino E, Li C, Song R, et al. Obesity as an effect modifier of the association between menstrual abnormalities and hypertension in young adult women: Results from project ELEFANT. *PLoS One* (2018) 13(11): e0207929. DOI: 10.1371/journal
11. Klump KL, Racine SE, Hildebrandt B, Burt SA, Neale M, Sisk CL, et al. Ovarian hormone influences on dysregulated eating: A comparison of associations in women with versus without binge episodes. *Clin Psychol Sci* (2014) 2(4):545–59. DOI: 10.1177/2167702614521794
12. RachońD, Teede H. Ovarian function, and obesity–interrelationship, impact on women's reproductive lifespan and treatment options. *Mol Cell Endocrinol* (2010) 316(2):172–9. DOI: 10.1016/j.mce.2009.09.026
13. Stewart CE, Sohrabji F. Gonadal hormones and stroke risk: PCOS as a case study. *Front Neuroendocrinol* (2020) 58:100853. DOI: 10.1016/j.yfrne.2020.100853
14. Kohlmeier A, Sison CAM, Yilmaz BD, Coon V JS, Dyson MT, Bulun SE. GATA2 and progesterone receptor interaction in endometrial stromal cells undergoing decidualization. *Endocrinology* (2020) 161(6):bqaa070. DOI: 10.1210/ endocr/gqaa070
15. Rhee JS, Saben JL, Mayer AL, Schulte MB, Asghar Z, Stephens C, et al. Diet-induced obesity impairs endometrial stromal cell decidualization: a potential role for impaired autophagy. *Hum Reprod* (2016) 31(6):1315–26. doi: 10.1093/humrep/ dew048
16. Yang T, Zhao J, Liu F, Li Y. Lipid metabolism and endometrial receptivity. *Hum Reprod Update* (2022) 27:dmac026. doi: 10.1093/humupd/dmac026
17. Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists. *J Clin Endocrinol Metab* (2020) 105(8):e2695–709. doi: 10.1210/clinem/dgaa285
18. Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. *J Clin Endocrinol Metab* (2020) 105(8):e2695–709. doi: 10.1210/clinem/dgaa285
19. De Medeiros SF, Rodgers RJ, Norman RJ. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome. *Hum Reprod Update* (2021) 27(4):771–96. doi: 10.1093/humupd/dmab004
20. Escobar-Morreale HF. Polycystic ovary syndrome: definition, etiology, diagnosis, and treatment. *Nat Rev Endocrinol* (2018) 14(5):270–84. doi: 10.1038/ nrendo.2018.24
21. Cho SH, Leonard SA, Lyndon A, Main EK, Abrams B, Hameed AB, et al. Pre-pregnancy obesity and the risk of peripartum cardiomyopathy. *Am J Perinatol* (2021) 38(12):1289–96. DOI: 10.1055/s-0040-1712451
22. Parretti S, Caroli A, Torlone E. Nutrition and metabolic adaptations in physiological and complicated pregnancy: focus on obesity and gestational diabetes. *Front Endocrinol (Lausanne)* (2020) 11(5):611929. DOI: 10.3389/ fendo.2020.611929

23. Leary C, Leese HJ, Sturmey RG. Human embryos from overweight and obese women display phenotypic and metabolic abnormalities. *Hum Reprod* (2015) 30(1):122–32. doi: 10.1093/humrep/deu276
24. Gaccioli F, Lager S, Powell TL, Jansson T. Placental transport in response to altered maternal nutrition. *J Dev Orig Health Dis* (2013) 4(2):101–15. DOI: 10.1017/S2040174412000529
25. Araujo-Silva VC, Santos-Silva A, Lourenço AS, Barros-Barbosa CM, Moraes-Souza RQ, et al. Congenital anomalies programmed by maternal diabetes and obesity on offspring of rats. *Front Physiol* (2021) 12:701767. doi: 10.3389/fphys.2021.701767
26. Groves AM, Price AN, Russell-Webster T, Jhaveri S, Yang Y, Battersby EE, et al. Impact of maternal obesity on neonatal heart rate and cardiac size. *Arch Dis Child Fetal Neonatal Ed* (2021) 17: fetalneonatal-2021-322860. DOI: 10.1136/archdischild-2021-322860
27. Xu T, Sheng Z, Yao L. Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics, and treatment. *Front Med* (2017) 11(3):340–8. DOI: 10.1007/s11684-017-0570-3
28. Castro BBA, Foresto-Neto O, Saraiva-Camara NO, Sanders-Pinheiro H. Renal lipotoxicity: Insights from experimental models. *Clin Exp Pharmacol Physiol* (2021) 48(12):1579–88. DOI: 10.1111/1440-1681.13556
29. Nehus E. Obesity and chronic kidney disease. *Curr Opin Pediatr* (2018) 30 (2):241–6. DOI: 10.1097/MOP.0000000000000586
30. Fritsche KL. The science of fatty acids and inflammation. *Adv Nutr* (2015) 6 (3):293S–301S. DOI: 10.3945/an.114.006940
31. De Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al. Fatty kidney: the emerging role of ectopic lipid in obesity-related renal disease. *Lancet Diabetes Endocrinol* (2014) 2(5):417–26. DOI: 10.1016/S2213-8587(14)70065-8
32. Yang P, Xiao Y, Luo X, Zhao Y, Zhao L, Wang Y, et al. Inflammatory stress promotes the development of obesity-related chronic kidney disease via CD36 in mice. *J Lipid Res* (2017) 58(7):1417–27. doi: 10.1194/jlr.M076216
33. Kim YJ, Hwang SD, Oh TJ, Kim KM, Jang HC, Kimm H, et al. Association between obesity and chronic kidney disease, defined by both glomerular filtration rate and albuminuria, in Korean adults. *Metab Syndr Relat Disord* (2017) 15 (8):416–22. DOI: 10.1089/met.2017.0053
34. Sun R, Liu M, Lu L, Zheng Y, Zhang P. Congenital heart disease: Causes, diagnosis, symptoms, and treatments. *Cell Biochem Biophys* (2015) 72(3):857–60. DOI: 10.1007/s12013-015-0551-6
35. Li MF, Ke JF, Ma L, Wang JW, Zhang ZH, Li JB, et al. Maternal pre-pregnancy obesity combined with abnormal glucose metabolism further increases adverse pregnancy outcomes in Chinese pregnant women. *Front Endocrinol (Lausanne)* (2002) 12:754406. doi: 10.3389/fendo.2021.754406
36. Helle E, Priest JR. Maternal obesity and diabetes mellitus as risk factors for congenital heart disease in the offspring. *J Am Heart Assoc* (2020) 9(8):e011541. doi: 10.1161/JAHA.119.011541
37. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. *J Am Coll Cardiol* (2014) 63(14):1345–54. doi: 10.1016/j.jacc.2014.01.022
38. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. *JACC Heart Fail* (2013) 1(2):93–102. DOI: 10.1016/j.jchf.2013.01.006
39. Mena GP, Mielke GI, Brown WJ. The effect of physical activity on reproductive health outcomes in young women: a systematic review and meta-analysis. *Hum Reprod Update* (2019) 25(5):541–63. doi: 10.1093/humupd/dmz013

40. Beets MW, von Klingraeff L, Burkart S, Jones A, Ioannidis JPA, Weaver RG, et al. Impact of risk of generalizability biases in adult obesity interventions: A meta-epidemiological review and meta-analysis. *Obes Rev* (2022) 23(2):e13369. DOI: 10.1111/or.13369

Appendix 1: Female Sexual Function Index Scoring

	Question	Response Options
1	Over the past 4 weeks, how often did you feel sexual desire or interest?	5 = Almost always or always 4 = Most times (more than half the time) 3 = Sometimes (about half the time) 2 = A few times (less than half the time) 1 = Almost never or never
2	Over the past 4 weeks, how would you rate your level (degree) of sexual desire or interest?	5 = Very high 4 = High 3 = Moderate 2 = Low 1 = Very low or none at all
3	Over the past 4 weeks, how often did you feel sexually aroused ("turned on") during sexual activity or intercourse?	0 = No sexual activity 5 = Almost always or always 4 = Most times (more than half the time) 3 = Sometimes (about half the time) 2 = A few times (less than half the time) 1 = Almost never or never
4	Over the past 4 weeks, how would you rate your level of sexual arousal ("turn on") during sexual activity or intercourse?	0 = No sexual activity 5 = Very high 4 = High 3 = Moderate 2 = Low 1 = Very low or none at all
5	Over the past 4 weeks, how confident were you about becoming sexually aroused during sexual activity or intercourse?	0 = No sexual activity 5 = Very high confidence 4 = High confidence 3 = Moderate confidence 2 = Low confidence 1 = Very low or no confidence
6	Over the past 4 weeks, how often have you been satisfied with your arousal (excitement) during sexual activity or intercourse?	0 = No sexual activity 5 = Almost always or always 4 = Most times (more than half the time) 3 = Sometimes (about half the time) 2 = A few times (less than half the time) 1 = Almost never or never
7	Over the past 4 weeks, how often did you become lubricated ("wet") during sexual activity or intercourse?	0 = No sexual activity 5 = Almost always or always 4 = Most times (more than half the time) 3 = Sometimes (about half the time) 2 = A few times (less than half the time) 1 = Almost never or never
8	Over the past 4 weeks, how difficult was it to become lubricated ("wet") during sexual activity or intercourse?	0 = No sexual activity 1 = Extremely difficult or impossible 2 = Very difficult 3 = Difficult

		4 = Slightly difficult 5 = Not difficult
9	Over the past 4 weeks, how often did you maintain your lubrication ("wetness") until completion of sexual activity or intercourse?	0 = No sexual activity 5 = Almost always or always 4 = Most times (more than half the time) 3 = Sometimes (about half the time) 2 = A few times (less than half the time) 1 = Almost never or never
10	Over the past 4 weeks, how difficult was it to maintain your lubrication ("wetness") until completion of sexual activity or intercourse?	0 = No sexual activity 1 = Extremely difficult or impossible 2 = Very difficult 3 = Difficult 4 = Slightly difficult 5 = Not difficult
11	Over the past 4 weeks, when you had sexual stimulation or intercourse, how often did you reach orgasm (climax)?	0 = No sexual activity 5 = Almost always or always 4 = Most times (more than half the time) 3 = Sometimes (about half the time) 2 = A few times (less than half the time) 1 = Almost never or never
12	Over the past 4 weeks, when you had sexual stimulation or intercourse, how difficult was it for you to reach orgasm (climax)?	0 = No sexual activity 1 = Extremely difficult or impossible 2 = Very difficult 3 = Difficult 4 = Slightly difficult 5 = Not difficult
13	Over the past 4 weeks, how satisfied were you with your ability to reach orgasm (climax) during sexual activity or intercourse?	0 = No sexual activity 5 = Very satisfied 4 = Moderately satisfied 3 = About equally satisfied and dissatisfied 2 = Moderately dissatisfied 1 = Very dissatisfied
14	Over the past 4 weeks, how satisfied have you been with the amount of emotional closeness during sexual activity between you and your partner?	0 = No sexual activity 5 = Very satisfied 4 = Moderately satisfied 3 = About equally satisfied and dissatisfied 2 = Moderately dissatisfied 1 = Very dissatisfied
15	Over the past 4 weeks, how satisfied have you been with your sexual relationship with your partner?	5 = Very satisfied 4 = Moderately satisfied 3 = About equally satisfied and dissatisfied 2 = Moderately dissatisfied 1 = Very dissatisfied
16	Over the past 4 weeks, how satisfied have you been with your overall sexual life?	5 = Very satisfied 4 = Moderately satisfied 3 = About equally satisfied and dissatisfied 2 = Moderately dissatisfied 1 = Very dissatisfied
17	Over the past 4 weeks, how often did you experience discomfort or pain during vaginal penetration?	0 = Did not attempt intercourse 1 = Almost always or always 2 = Most times (more than half the time) 3 = Sometimes (about half the time) 4 = A few times (less than half the time) 5 = Almost never or never
18	Over the past 4 weeks, how often did you experience discomfort or pain following vaginal	0 = Did not attempt intercourse 1 = Almost always or always 2 = Most times (more than half the time)

	penetration?	3 = Sometimes (about half the time) 4 = A few times (less than half the time) 5 = Almost never or never
19	Over the past 4 weeks, how would you rate your level (degree) of discomfort or pain during or following vaginal penetration?	0 = Did not attempt intercourse 1 = Very high 2 = High 3 = Moderate 4 = Low 5 = Very low or none at all

Appendix 2: Female Sexual Function Index Domain Scores and Full Scale Score

The individual domain scores and full scale (overall) score of the FSFI can be derived from the computational formula outlined in the table below. For individual domain scores, add the scores of the individual items that comprise the domain and multiply the sum by the domain factor (see below). Add the six domain scores to obtain the full scale score. It should be noted that within the individual domains, a domain score of zero indicates that the subject reported having no sexual activity during the past month. Subject scores can be entered in the right hand column.

Domain	Questions	Score Range	Factor	Minimum Score	Maximum Score	Score
Desire	1, 2	1 – 5	0.6	1.2	6.0	
Arousal	3, 4, 5, 6	0 – 5	0.3	0	6.0	
Lubrication	7, 8, 9, 10	0 – 5	0.3	0	6.0	
Orgasm	11, 12, 13	0 – 5	0.4	0	6.0	
Satisfaction	14, 15, 16	0 (or 1) – 5	0.4	0.8	6.0	
Pain	17, 18, 19	0 – 5	0.4	0	6.0	
Full Scale Score Range				2.0	36.0	

FSFI Questionnaire. Available at:

www.fsf-questionnaire.com/FSFI%20Scoring%20Appendix.pdf. Retrieved December 19, 2011. Reproduced with permission from the publisher (Taylor & Francis Ltd, <http://www.tandf.co.uk/journals>). Also published in Reed SD, Guthrie KA, Joffe H, Shifren JL, Seguin RA, and Freeman EW. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. *Obstet Gynecol* 2012; 119: 527–38.

Reed SD, Mitchell CM, Joffe H, Cohen L, Shifren JL, Newton KM, et al. Sexual function in women on estradiol or venlafaxine for hot flashes: a randomized controlled trial. *Obstet Gynecol* 2014; 124.

The authors provided this information as a supplement to their article.

© Copyright 2014 American College of Obstetricians and Gynecologists.